Articles published by Verastem Oncology
![](https://mms.businesswire.com/media/20240808951114/en/2211261/22/Verastem_logo_v2.jpg)
Verastem Oncology Reports Second Quarter 2024 Financial Results and Highlights Recent Business Updates
August 08, 2024
From Verastem Oncology
Via Business Wire
Tickers
VSTM
![](https://mms.businesswire.com/media/20240729473398/en/2199333/22/Verastem_logo_v2.jpg)
![](https://mms.businesswire.com/media/20240723132805/en/2194826/22/5516636cVerastem_logo_v2.jpg)
![](https://mms.businesswire.com/media/20240723232443/en/2194055/22/Verastem_logo_v2.jpg)
Verastem Oncology Announces Proposed Public Offering of Common Stock, Warrants and Pre-Funded Warrants
July 23, 2024
From Verastem Oncology
Via Business Wire
Tickers
VSTM
![](https://mms.businesswire.com/media/20240712883632/en/2184152/22/Verastem_logo_v2.jpg)
![](https://mms.businesswire.com/media/20240708142554/en/2176999/22/Verastem_logo_v2.jpg)
![](https://mms.businesswire.com/media/20240701632456/en/2174389/22/Verastem_logo_v2.jpg)
![](https://mms.businesswire.com/media/20240524990712/en/2140664/22/Verastem_logo_v2.jpg)
![](https://mms.businesswire.com/media/20240523300933/en/2140508/22/Verastem_logo_v2.jpg)
![](https://mms.businesswire.com/media/20240509453333/en/2126404/22/Verastem_logo_v2.jpg)
![](https://mms.businesswire.com/media/20240507625461/en/2121605/22/Verastem_logo_v2.jpg)
![](https://mms.businesswire.com/media/20240418758500/en/2102901/22/Verastem_logo_v2.jpg)
Verastem Oncology Announces Appointment of John Hayslip, M.D., to Chief Medical Officer
April 18, 2024
From Verastem Oncology
Via Business Wire
Tickers
VSTM
![](https://mms.businesswire.com/media/20240404745728/en/2088541/22/Verastem_logo.jpg)
![](https://mms.businesswire.com/media/20240318242065/en/2068756/22/Verastem_logo_v2.jpg)
![](https://mms.businesswire.com/media/20240314845611/en/2067630/22/Verastem_logo_v2.jpg)
![](https://mms.businesswire.com/media/20240311346009/en/2060624/22/5417622cVerastem_logo_v2.jpg)
![](https://mms.businesswire.com/media/20240305616374/en/2056148/22/5417622cVerastem_logo_v2.jpg)
![](https://mms.businesswire.com/media/20240305290262/en/2055717/22/Verastem_logo_v2.jpg)
![](https://mms.businesswire.com/media/20240124822477/en/2009162/22/Verastem_logo_v2.jpg)
![](https://mms.businesswire.com/media/20240118664635/en/2002889/22/Verastem_logo_v2.jpg)
![](https://mms.businesswire.com/media/20240111104814/en/1992573/22/Verastem_logo_v2.jpg)
Verastem Oncology to Participate in the B. Riley Securities 4th Annual Oncology Conference
January 11, 2024
From Verastem Oncology
Via Business Wire
Tickers
VSTM
![](https://mms.businesswire.com/media/20240105841478/en/1989194/5/Verastem_logo.jpg)
![](https://mms.businesswire.com/media/20231218660514/en/1972188/5/Verastem_logo_jpg.jpg)
![](https://mms.businesswire.com/media/20231213489476/en/1968591/5/VSTM_Logo.jpg)
![](https://mms.businesswire.com/media/20231113852336/en/1942808/5/VSTM_Logo.jpg)
![](https://mms.businesswire.com/media/20231108803454/en/1939360/5/VSTM_Logo.jpg)
Verastem Oncology Reports Third Quarter 2023 Financial Results and Highlights Recent Company Progress
November 08, 2023
From Verastem Oncology
Via Business Wire
Tickers
VSTM
![](https://mms.businesswire.com/media/20231107926726/en/1935265/22/LGSOC_Patient_Impact_Survey_Findings.jpg)
![](https://mms.businesswire.com/media/20231106345111/en/1934583/22/ee155111e9be52b8cce1601ca19e4d0b.jpg)
![](https://mms.businesswire.com/media/20231026794275/en/1927029/22/Verastem_Logo_Oct_23.jpg)
![](https://mms.businesswire.com/media/20231018337292/en/1919457/22/Verastem_Logo_Oct_23.jpg)
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.